Related Experiment Video
Updated: Aug 6, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
From biomarker expansion to equitable implementation in mild cognitive impairment
Mashal Khan1, Talha Khan2, Ayesha Tariq3
1Women Medical College, Abbottabad Affiliated with Khyber Medical University, Peshawar, Pakistan.
Summary
Cerebrospinal fluid (CSF) biomarker testing aids Alzheimer's diagnosis, especially for mild cognitive impairment (MCI). However, widespread use faces infrastructure, access, and ethical hurdles for equitable dementia care.
Area of Science:
- Neurology
- Biomarker Research
- Dementia Diagnostics
Background:
- Cerebrospinal fluid (CSF) biomarkers are increasingly vital for diagnosing Alzheimer's disease (AD).
- The advent of anti-amyloid therapies necessitates refined diagnostic strategies for mild cognitive impairment (MCI).
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...